HugoScore hugoscore.org

Coverage appeal AI

Claimable

Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.

Document-based draft Read full report Open directory

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Mixed7 of 12 agency checks metDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist · October 30, 2026

Mixed 7 of 12 yes

Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.

Assessed function: Claimable patient appeal workflow (patient-facing AI-drafted insurance appeals, including pharma/provider-sponsored referrals); enterprise analytics for pharma and health systems not assessed

A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.

  • Public documents do not establish actual product behavior.
  • The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
QuestionAnswerEvidence / reviewSource and reasoning
1. Told it is AIYesdocumented
Not independently replicated
utilizing our artificial intelligence driven software solution Source

AI is disclosed in the Terms of Service (Service section) and throughout the site. A separate in-product consent screen was not observed (login required).

2. Operator and model maker namedNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Claimable, Inc. is named as operator. No public source names the maker of the language model. The AI blog says only 'custom-built technology', 'large language models' and NVIDIA Inception membership.

3. Patient chooses to use itYesdocumented
Not independently replicated
account holders themselves and individuals (e.g. child or elderly parent) whom account holders choose to assist in filing of appeals Source

Patient creates an account and completes intake. Referrals from pharma, pharmacies or providers exist (for-pharma FAQ: 'invited through direct referral or self-enrollment'), but the patient still starts and approves the appeal.

4. Patient sets the taskYesdocumented
Not independently replicated
Patients remain the decision-makers, and AI simply structures their story with supporting evidence. Source

Statement is from the partner-facing page, not a binding document. Sponsored programs are disclosed 'during consent' per the same page. Whether sponsored flows steer patients toward a sponsor's drug was not tested.

5. Patient can decline or stopYesdocumented
Not independently replicated
account holders themselves and individuals (e.g. child or elderly parent) whom account holders choose to assist in filing of appeals Source

Self-started rule applied. Also: 'nothing is sent without their approval' (for-pharma FAQ).

6. Patient sees the AI outputYesdocumented
Not independently replicated
you review the final document before anything is submitted Source

Patient sees the AI-drafted appeal before submission.

7. Patient can correct or challengeYesdocumented
Not independently replicated
Patients verify accuracy, make edits, and authorize submission Source

Edit and flag route documented in partner FAQ and for-providers page ('can make any changes before it's sent'); the AI blog says patients can 'mark it for further examination'.

8. Patient can get a copyNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Privacy policy lets users 'review and update certain Claimable account information'. No export or download of the appeal or data is documented. The Data Request Form is mentioned only for marketing opt-out.

9. Patient can deleteYesdocumented
Not independently replicated
You can request that we delete your account by contacting us with your account deletion request or deleting your account through the Services. Source

Terms say Claim Data 'may be deleted and not be retrievable' on account deletion, but the same Terms grant Claimable a perpetual, irrevocable license to Claim Data. What survives deletion is unclear.

10. Training or sale does not override patient choiceNodocumented
Not independently replicated
when aggregated and anonymized, any other purpose in any form, format, or media that we choose Source

Binding Terms (section 6) and Privacy ('research and development', sharing de-identified data) allow reuse. The AI blog says the AI 'is trained to recognize patterns in successful appeals'. No opt-out is documented. The safe-sharing blog says data is not sold or shared, which conflicts with the binding documents. Answered by the binding documents.

11. Patient can run it or take it elsewhereNonot-documented
Not independently replicated
Quotation not recorded; evidence repair pending. Source

Vendor-hosted only. Terms grant a revocable, non-transferable right to use the Service. No self-hosting or portability.

12. No advertising or data businessNodocumented
Not independently replicated
We may use this aggregated, de-identified or otherwise anonymized data and share it with third parties for our lawful business purposes Source

Privacy also allows sharing with 'licensors or partners' for 'their analysis or marketing purposes subject to your consent', and CCPA 'sale' of device data. The for-pharma page markets 'aggregate analytics' of insurer denial patterns to manufacturers. Terms allow fees to be waived when sponsored by pharma or providers.

Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.

Checklist rules · Independent review and limitations · Later evidence follow-up

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

Leans expandsEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Potentially agency-expanding, with sponsorship-alignment caveat

Legacy editorial placement, pre-method: 72

This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does Claimable serve in this deployment?
Control Claimable patient appeal workflow (patient-facing AI-drafted insurance appeals, including pharma/provider-sponsored referrals); enterprise analytics for pharma and health systems not assessed
Agency read Mixed
Vendor
Claimable, Inc.
Who it serves
Patient-directed appeal workflow, including sponsored referrals
Primary User
Patients and caregivers appealing medication denials, plus pharma patient-support, health-system, and provider teams on the enterprise side
Control Model
Vendor-hosted public service. Controls and downstream processors depend on the assessed deployment.
Patient Impact
drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.
Profile Status
Document-based draft
Last assessed
Oct 30, 2026
Earlier review confidence
Medium for published documentation, low for implementation (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 72

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 72. Not comparable with v1.3 positions.

Potentially agency-expanding, with sponsorship-alignment caveat

Claimable’s patient appeal workflow, including sponsored referrals, documents patient editing and approval before delivery. Enterprise analytics have a separate scope. Sponsorship and contradictory sharing language require scrutiny, with implementation unverified.

Patient agency

How this tool changes agency

Expands agency when

drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.

Limits agency when

Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.

Patient agency assessment

Who sets and changes the goal?

Patient authority

the documented approval gate supports patient direction within the appeal task. Provider referral and sponsorship do not erase that gate. Authority over a different treatment goal or enterprise strategy is not established.

What can the patient understand, question, or do?

Critical capacity

drafting and delivery can make contesting a denial practically possible. Evidence-backed argument is a documented product claim, not verified citation quality or proof of broader critical understanding.

Can the patient evaluate the conditions of use?

Informed control

the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.

Text findings

Conditions of use

Published controls and their limits

the public controls are meaningful, but contradictory sharing language and unobserved consent limit confidence in how patients evaluate the service's conditions. Commercial interests may coincide with a chosen appeal without encompassing all patient interests.

What remains unknown?

Not tested or not established

Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows.

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Consent presentation, independent output-use rights, control outside the supported appeal goal, and actual partner data flows. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Document-based draft · Medium for published documentation, low for implementation (AI-assisted draft)